Johnson & Johnson (NYSE:JNJ) Stake Increased by Keystone Wealth Services LLC

Keystone Wealth Services LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 8,022 shares of the company’s stock after buying an additional 106 shares during the quarter. Keystone Wealth Services LLC’s holdings in Johnson & Johnson were worth $1,310,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after buying an additional 3,912,430 shares in the last quarter. Legal & General Group Plc boosted its holdings in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. FMR LLC boosted its holdings in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after acquiring an additional 24,505 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.5 %

NYSE:JNJ opened at $168.74 on Friday. The stock has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56. The firm has a fifty day simple moving average of $176.14 and a two-hundred day simple moving average of $171.25. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 277,886 shares of company stock worth $48,550,549. 0.35% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Finally, Bank of America cut their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.